Abstract: A biodegradable and biocompatible polyurethane composition synthesized by reacting isocyanate groups of at least one multifunctional isocyanate compound with at least one bioactive agent having at least one reactive group —X which is a hydroxyl group (—OH) or an amine group (—NH2). The polyurethane composition is biodegradable within a living organism to biocompatible degradation products including the bioactive agent. Preferably, the released bioactive agent affects at least one of biological activity or chemical activity in the host organism. A biodegradable polyurethane composition includes hard segments and soft segments. Each of the hard segments is preferably derived from a diurea diol or a diester diol and is preferably biodegradable into biomolecule degradation products or into biomolecule degradation products and a biocompatible diol. Another biodegradable polyurethane composition includes hard segments and soft segments.

Abstract: A biodegradable and biocompatible polyurethane composition synthesized by reacting isocyanate groups of at least one multifunctional isocyanate compound with at least one bioactive agent having at least one reactive group —X which is a hydroxyl group (—OH) or an amine group (—NH2). The polyurethane composition is biodegradable within a living organism to biocompatible degradation products including the bioactive agent. Preferably, the released bioactive agent affects at least one of biological activity or chemical activity in the host organism. A biodegradable polyurethane composition includes hard segments and soft segments. Each of the hard segments is preferably derived from a diurea diol or a diester diol and is preferably biodegradable into biomolecule degradation products or into biomolecule degradation products and a biocompatible diol. Another biodegradable polyurethane composition includes hard segments and soft segments.

Abstract: A pharmaceutical composition comprising in combination the Runx2 protein, a polynucleotide encoding the Runx2 protein, or a cell that has been transformed with a polynucleotide encoding Runx2 protein, in a pharmaceutically acceptable carrier, the carrier comprising a bio-compatible, biodegradable polymeric matrix. Another aspect of the present invention includes a device comprising the above-described pharmaceutical composition in combination with a sterile and substantially antigen-free, pre-shaped allograft or xenograft bone implant. Also contemplated herein is a method for repairing a bone defect comprising administering to a mammalian patient at the site in need of treatment a pharmaceutical composition, comprising in combination the Runx2 protein, a polynucleotide encoding the Runx2 protein, or a cell that has been transformed with a polynucleotide encoding Runx2 protein, in a pharmaceutically acceptable carrier wherein the carrier is a bio-compatible, biodegradable polymeric matrix.